Please use this identifier to cite or link to this item:
Title: Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: a protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA)
Decs: Medicina Individualizada; Artritis Reumatoide; Prediccion;
Issue Date: 31-Aug-2020
Publisher: Springer Nature
Citation: Trials.2020 Aug;(21)1:755
Abstract: Rheumatoid arthritis (RA) is one of the leading chronic inflammatory rheumatism. First-line therapy with synthetic disease-modifying antirheumatic drugs (sDMARD) is insufficiently effective in 40% of cases and these patients are treated with biotherapies. The increased use of these drugs each year is becoming a public health issue with considerable economic burden. This cost is 20 times higher than that of sDMARD. However, among patients treated with biotherapies, clinical practice shows that about one third will not respond to the selected drug. In nonresponse cases, practitioners currently have no choice but to perform an empirical switching between different treatments, because no tool capable of predicting the response or nonresponse to these molecules is currently available.
Rights: Atribución-NoComercial-SinDerivadas 3.0 España
ISSN: 1745-6215
Appears in Collections:Hospitales > H. U. Clínico San Carlos > Artículos

Files in This Item:
File Description SizeFormat 
document.pdf657.47 kBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons